Q-omics provides the consensus-scored MYO5B profile across patient tissues and cancer cell-line models. MYO5B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MYO5B is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, MYO5B RNA expression shows 19,758 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, BLCA, and THYM as cancer lineages where MYO5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO5B survival associations across molecular data types. MYO5B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO5B RNA expression–survival associations across cancer types. High MYO5B expression shows unfavorable associations in UVM, PAAD and LGG, but favorable associations in KIRP, KIRC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MYO5B RNA expression.
This table summarizes MYO5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYO5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO5B shows lower tumor expression in HNSC and KIRC and higher tumor expression in BLCA, UCEC, STAD and BRCA. The BLCA box plot shows higher MYO5B RNA expression in tumor versus normal tissue (log2 FC = +1.548, t-test p = .002).
This table shows molecular features associated with MYO5B in patient tissues and cancer cell lines. In patient samples, MYO5B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
